EXPLORING HIDDEN SURVIVAL HETEROGENEITY AMONG FIRST-LINE (1L) INTERMEDIATE/POOR (I/P)-RISK ADVANCED RENAL CELL CARCINOMA (ARCC) PATIENTS TREATED WITH NIVOLUMAB PLUS IPILIMUMAB (NIVO plus IPI) VIA PARAMETRIC MIXTURE MODELS (PMM)

被引：0
|
作者：
Hunger, M. [1 ]
George, S. [2 ]
Dyer, M. [3 ]
Ejzykowicz, F. [4 ]
May, J. R. [3 ]
Kurt, M. [5 ]
机构：
[1] ICON Plc, Munich, Germany
[2] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[3] Bristol Myers Squibb, Uxbridge, Middx, England
[4] Bristol Myers Squibb, Lawrenceville, NJ USA
[5] Bristol Myers Squibb, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
MSR54
引用
收藏
页码：S287 / S287
页数：1
相关论文
共 50 条
  • [1] Prognostic factors for Overall Survival (OS) in patients receiving First-line (1L) Nivolumab plus Ipilimumab (NIVO plus IPI) for advanced/metastatic Renal Cell Carcinoma (aRCC) in a real-world setting in Germany
    Bedke, J.
    Gruenwald, V.
    Mueller-Huesmann, H.
    Belz, H.
    Von Der Heyde, E.
    Boegemann, M.
    Strauss, A.
    Vaz, L.
    Bluhmki, T.
    Herber, M.
    Groetzinger, S.
    Grimm, M-O.
    EUROPEAN UROLOGY, 2024, 85 : S1844 - S1845
  • [2] Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO plus IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.
    Tannir, Nizar M.
    Motzer, Robert J.
    Albiges, Laurence
    Plimack, Elizabeth R.
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Rini, Brian, I
    Grunwald, Viktor
    Hammers, Hans J.
    Choueiri, Toni K.
    Gurney, Howard
    Tykodi, Scott S.
    Porta, Camillo
    Burotto, Mauricio
    Tomita, Yoshihiko
    Lee, Chung-Wei
    Tang, Chad
    McDermott, David F.
    McKay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [3] A COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB PLUS IPILIMUMAB (NIVO plus IPI) VS PEMBROLIZUMAB PLUS AXITINIB (PEM plus AXI) FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE OR POOR (I/P)-RISK ADVANCED RENAL CELL CARCINOMA PATIENTS IN PERU
    Youn, J. H.
    Jain, D.
    Guiot, V
    Velarde, J.
    Garcia, Perlaza J.
    Dyer, M.
    VALUE IN HEALTH, 2024, 27 (06) : S142 - S142
  • [4] Real-world (RW) outcomes in metastatic renal cell carcinoma (mRCC) patients treated with first-line (1L) nivolumab plus ipilimumab (NIVO plus IPI) in the United States
    Geynisman, D.
    Chan, P.
    Robert, N.
    Chen, L.
    Del Tejo, V.
    Rosenblatt, L. C.
    Huo, S.
    Doshi, G.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1216 - S1216
  • [5] Comparative effectiveness of first-line (1L) ipilimumab plus nivolumab (Ipi plus Nivo) versus immune checkpoint inhibitors plus tyrosine kinase inhibitors (ICI plus TKI) in patients (pts) with intermediate or poor (I/P) risk metastatic clear cell renal cell carcinoma (mccRCC)
    Ostrowski, Micah
    Jo, Yeonjung
    Gebrael, Georges
    Chehade, Chadi Hage
    Narang, Arshit
    Fortuna, Gliceida Galarza
    Thomas, Vinay Mathew
    Chigarira, Beverly
    Anderson, Ethan
    Mazumder, Archisman
    Ozay, Zeynep Irem
    Agarwal, Neeraj
    Maughan, Benjamin L.
    Swami, Umang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB PLUS IPILIMUMAB (NIVO plus IPI) VERSUS PEMBROLIZUMAB PLUS AXITINIB (PEM plus AXI) FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- AND POOR (I/P)-RISK ADVANCED RENAL CELL CARCINOMA PATIENTS IN COLOMBIA
    Dhanji, N.
    Van, De Wetering G.
    Guiot, V
    Barco, V
    Mejia, A.
    May, J. R.
    Garcia, J.
    Dyer, M.
    VALUE IN HEALTH, 2023, 26 (06) : S74 - S74
  • [7] Long-term survivorship rates for first-line intermediate or poor (I/P) risk advanced renal cell carcinoma (aRCC) patients achieving objective response (OR) with nivolumab plus ipilimumab (N plus I)
    George, S.
    Hunger, M.
    Hughes, O.
    May, J. R.
    Dyer, M.
    Ejzykowicz, F.
    Kurt, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1210 - S1211
  • [8] ESTIMATING LONG-TERM SURVIVORSHIP RATES FOR PREVIOUSLY UNTREATED INTERMEDIATE OR POOR (I/P) RISK ADVANCED RENAL CELL CARCINOMA (ARCC) PATIENTS TREATED WITH NIVOLUMAB PLUS IPILIMUMAB (NIVO plus IPI): ANALYSES FROM THE CHECKMATE 214 TRIAL
    Paly, V
    George, S.
    Youn, J. H.
    Borrill, J.
    Ejzykowicz, F.
    May, J. R.
    Kurt, M.
    VALUE IN HEALTH, 2022, 25 (01) : S210 - S210
  • [9] Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO plus RELA) versus NIVO plus ipilimumab (NIVO plus IPI) in advanced melanoma: An updated indirect treatment comparison (ITC)
    Schadendorf, Dirk
    Tawbi, Hussein A.
    Lipson, Evan J.
    Hodi, F. Stephen
    Ascierto, Paolo Antonio
    Larkin, James
    Lao, Christopher D.
    Grob, Jean-Jacques
    Ejzykowicz, Flavia
    Palaia, Jennell
    Horton, Viviana Garcia
    Zhou, Zheng-Yi
    Christensen, Dana
    Rosenblatt, Lisa
    McDonald, Laura
    Ratto, Barbara
    Salvatore, Anthony
    Patel, Divya
    Sakkal, Leon A.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] UPDATED LIFETIME SURVIVAL ESTIMATES FOR NIVOLUMAB plus IPILIMUMAB IN PREVIOUSLY UNTREATED ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA (1L ARCC)
    Qendri, V
    May, J.
    Malcolm, B.
    Ejzykowicz, F.
    Kurt, M.
    Cakar, E.
    Klijn, S.
    VALUE IN HEALTH, 2020, 23 : S520 - S520
12345